Details
Stereochemistry | ACHIRAL |
Molecular Formula | C10H13N2O3.Na |
Molecular Weight | 232.2116 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].CC(C)C1(CC=C)C(=O)NC(=O)[N-]C1=O
InChI
InChIKey=HLFOAHHCDKJHCJ-UHFFFAOYSA-M
InChI=1S/C10H14N2O3.Na/c1-4-5-10(6(2)3)7(13)11-9(15)12-8(10)14;/h4,6H,1,5H2,2-3H3,(H2,11,12,13,14,15);/q;+1/p-1
DescriptionSources: https://www.drugs.com/mmx/aprobarbital.html
Sources: https://www.drugs.com/mmx/aprobarbital.html
Aprobarbital is a barbiturate derivative. Aprobarbital have been used for the short-term treatment of insomnia and for routine sedation to relieve anxiety, tension, and apprehension however, barbiturates generally have been replaced by benzodiazepines.
CNS Activity
Originator
Sources: http://www.trademarkia.com/alurate-71245642.html | https://en.wikipedia.org/wiki/Aprobarbital
Curator's Comment: On Saturday, March 12, 1927, a U.S. federal trademark registration was filed for ALURATE (trade name for Aprobarbital) by Hoffmann-La Roche Inc.. According to Wikipedia Aprobarbital was invented in the 1920s by Ernst Preiswerk (No additional reference available). # Hoffmann-La Roche Inc.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2093872 Sources: https://www.drugbank.ca/drugs/DB01352 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | ALURATE Approved UseAprobarbital have been used for the short-term treatment of insomnia and for routine sedation to relieve anxiety, tension, and apprehension however, barbiturates generally have been replaced by benzodiazepines. Launch Date1927 |
|||
Primary | ALURATE Approved UseAprobarbital have been used for the short-term treatment of insomnia and for routine sedation to relieve anxiety, tension, and apprehension however, barbiturates generally have been replaced by benzodiazepines. Launch Date1927 |
PubMed
Title | Date | PubMed |
---|---|---|
Permanent impairment of renal function after methicillin nephropathy. | 1971 Nov 13 |
|
Determination of zidovudine/lamivudine/nevirapine in human plasma using ion-pair HPLC. | 2002 Jun 1 |
|
Determinations of zidovudine/didanosine/nevirapine and zidovudine/didanosine/ritonavir in human serum by micellar electrokinetic chromatography. | 2002 Nov 7 |
|
Determination of lamivudine/stavudine/efavirenz in human serum using liquid chromatography/electrospray tandem mass spectrometry with ionization polarity switch. | 2002 Sep |
|
The history of barbiturates a century after their clinical introduction. | 2005 Dec |
|
Occurrence and fate of barbiturates in the aquatic environment. | 2006 Dec 1 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/mmx/aprobarbital.html
Usual adult dose
Hypnotic: Oral, 40 to 160 mg at bedtime.
Sedative: Daytime—Oral, 40 mg three times a day.
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
DEA NO. |
2100
Created by
admin on Sat Dec 16 01:57:35 GMT 2023 , Edited by admin on Sat Dec 16 01:57:35 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
120767
Created by
admin on Sat Dec 16 01:57:35 GMT 2023 , Edited by admin on Sat Dec 16 01:57:35 GMT 2023
|
PRIMARY | |||
|
m2015
Created by
admin on Sat Dec 16 01:57:35 GMT 2023 , Edited by admin on Sat Dec 16 01:57:35 GMT 2023
|
PRIMARY | Merck Index | ||
|
23662380
Created by
admin on Sat Dec 16 01:57:35 GMT 2023 , Edited by admin on Sat Dec 16 01:57:35 GMT 2023
|
PRIMARY | |||
|
125-88-2
Created by
admin on Sat Dec 16 01:57:35 GMT 2023 , Edited by admin on Sat Dec 16 01:57:35 GMT 2023
|
PRIMARY | |||
|
DBSALT002230
Created by
admin on Sat Dec 16 01:57:35 GMT 2023 , Edited by admin on Sat Dec 16 01:57:35 GMT 2023
|
PRIMARY | |||
|
204-760-6
Created by
admin on Sat Dec 16 01:57:35 GMT 2023 , Edited by admin on Sat Dec 16 01:57:35 GMT 2023
|
PRIMARY | |||
|
6T90V76R18
Created by
admin on Sat Dec 16 01:57:35 GMT 2023 , Edited by admin on Sat Dec 16 01:57:35 GMT 2023
|
PRIMARY |
SALT/SOLVATE (PARENT)
SUBSTANCE RECORD